Literature DB >> 16752222

An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors.

Jing Fan1, Roberta McKean-Cowdin, Leslie Bernstein, Frank Z Stanczyk, Arthur Xuejun Li, Rachel Ballard-Barbash, Anne McTiernan, Richard Baumgartner, Frank Gilliland.   

Abstract

Insulin receptor substrate-1 (IRS-1) is a key downstream signaling molecule common to both the insulin and IGF signaling pathways that can interact with the estrogen pathway to regulate breast cell growth. We investigated whether a putative functional variant for IRS-1 (G972R) influences circulating levels of sex hormones, sex hormone binding globulin (SHBG), C-peptide, and insulin-like growth factor 1 (IGF-1) levels among post-menopausal African-American and non-Hispanic white breast cancer patients enrolled in the Health, Eating, Activity, and Lifestyle (HEAL) Study. Circulating levels of sex hormones and growth factors can influence breast cancer recurrence and survival. Serum estrone, estradiol, testosterone, SHBG, IGF-1 and C-peptide were measured in 468 patients at 30+ months post diagnosis. Non-protein bound hormone levels (free estradiol, free testosterone) were calculated. In African-American patients, the IRS-1 variant was associated with increased serum levels of estrone (p = 0.02), free estradiol (p = 0.04), total testosterone (p = 0.04), free testosterone (p = 0.006) and decreased levels of sex hormone-binding globulin (p = 0.02). No association was present for white patients. Our findings provide suggestive evidence that IRS-1 G972R variant may be associated with circulating levels of sex hormones and SHBG in African American breast cancer survivors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16752222      PMCID: PMC3063148          DOI: 10.1007/s10549-006-9211-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  66 in total

1.  Ethnic differences in risk and prognostic factors for breast cancer.

Authors:  S E Weiss; P I Tartter; S Ahmed; S T Brower; C Brusco; K Bossolt; J B Amberson; J Bratton
Journal:  Cancer       Date:  1995-07-15       Impact factor: 6.860

2.  Racial differences in survival of female breast cancer in the Detroit metropolitan area.

Authors:  M S Simon; R K Severson
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

3.  Human insulin receptor substrate-1: variant sequences in familial non-insulin-dependent diabetes mellitus.

Authors:  M Armstrong; F Haldane; R W Taylor; D Humphriss; T Berrish; M W Stewart; D M Turnbull; K G Alberti; M Walker
Journal:  Diabet Med       Date:  1996-02       Impact factor: 4.359

4.  Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice.

Authors:  T Yamauchi; K Tobe; H Tamemoto; K Ueki; Y Kaburagi; R Yamamoto-Honda; Y Takahashi; F Yoshizawa; S Aizawa; Y Akanuma; N Sonenberg; Y Yazaki; T Kadowaki
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

5.  A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies.

Authors:  K Almind; G Inoue; O Pedersen; C R Kahn
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

6.  Insulin receptor substrate-1 variants in non-insulin-dependent diabetes.

Authors:  M Laakso; M Malkki; P Kekäläinen; J Kuusisto; S S Deeb
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  No association between the Gly971Arg variant of the insulin receptor substrate 1 gene and NIDDM in the Taiwanese population.

Authors:  L M Chuang; C S Lai; J I Yeh; H P Wu; T Y Tai; B J Lin
Journal:  Diabetes Care       Date:  1996-05       Impact factor: 19.112

8.  Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1.

Authors:  J O Clausen; T Hansen; C Bjørbaek; S M Echwald; S A Urhammer; S Rasmussen; C B Andersen; L Hansen; K Almind; K Winther
Journal:  Lancet       Date:  1995-08-12       Impact factor: 79.321

9.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

Review 10.  The insulin-like growth factor system as a target in breast cancer.

Authors:  D Yee
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more
  3 in total

1.  A cluster randomized controlled trial to increase breast cancer screening among African American women: the black cosmetologists promoting health program.

Authors:  Georgia Robins Sadler; Celine M Ko; Phillis Wu; Jennifer Alisangco; Sheila F Castañeda; Colleen Kelly
Journal:  J Natl Med Assoc       Date:  2011-08       Impact factor: 1.798

2.  Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.

Authors:  Ning Xu; Kent D Taylor; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2009-03-26       Impact factor: 7.329

Review 3.  Insulin receptor substrates (IRSs) and breast tumorigenesis.

Authors:  Bonita Tak-Yee Chan; Adrian V Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.